GLP1R and type 2 diabetes mellitus: Accumulating evidence from multiple CVOTs for SGLT2 inhibitors and GLP-1R agonists has resulted in major excitement in the fields of cardiovascular endocrinology and diabetic cardiology, as these agents display strong signs of cardioprotection in people with T2DM.